Findings

What do systematic reviews say?

2,973 questions · 3,072 findings · 410 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 559 · 18.2%GRADE not reported 143 · 4.7%Very low 654 · 21.3%Low 833 · 27.1%Moderate 683 · 22.2%High 200 · 6.5%

Summary of findings for AMBMT vs PR

Change in dyspnoea score · patients with chronic obstructive pulmonary disease

2 findings from 1 review

Active mind‐body movement therapies as an adjunct to or in comparison with pulmonary rehabilitation for people with… 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 11 participants
Very low
Active mind‐body movement therapies as an adjunct to or in comparison with pulmonary rehabilitation for people with… 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 139 participants
Very low

Summary of findings for AMBMT vs PR

Dyspnoea ‐ change in mMRC Scale 0 to 4. Lower is better and 1 unit is a clinically important difference · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Active mind‐body movement therapies as an adjunct to or in comparison with pulmonary rehabilitation for people with… 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 127 participants
Very low

Summary of findings for AMBMT vs PR

Adverse eventsf · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Active mind‐body movement therapies as an adjunct to or in comparison with pulmonary rehabilitation for people with… 2018 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 490 participants
GRADE not reported

Summary of findings for AMBMT + PR vs PR

General health‐related quality of life · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Active mind‐body movement therapies as an adjunct to or in comparison with pulmonary rehabilitation for people with… 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 80 participants
Very low

Summary of findings for AMBMT + PR vs PR

Health‐related quality of life (mental) · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Active mind‐body movement therapies as an adjunct to or in comparison with pulmonary rehabilitation for people with… 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 80 participants
Very low

Summary of findings for AMBMT + PR vs PR

Units of SGRQ change from baseline · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Active mind‐body movement therapies as an adjunct to or in comparison with pulmonary rehabilitation for people with… 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 192 participants
Moderate

Selective serotonin reuptake inhibitors vs placebo

Change in quality of life · chronic obstructive pulmonary disease (COPD) with depression

1 finding from 1 review

Pharmacological interventions for the treatment of depression in chronic obstructive pulmonary disease 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 148 participants
Very low

Selective serotonin reuptake inhibitors vs placebo

Change in dyspnoea score · chronic obstructive pulmonary disease (COPD) with depression

1 finding from 1 review

Pharmacological interventions for the treatment of depression in chronic obstructive pulmonary disease 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 23 participants
Very low

Selective serotonin reuptake inhibitors vs placebo

Lung function: FEV1 mL (change from baseline) · chronic obstructive pulmonary disease (COPD) with depression

1 finding from 1 review

Pharmacological interventions for the treatment of depression in chronic obstructive pulmonary disease 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 148 participants
Very low

Selective serotonin reuptake inhibitors vs placebo

Change in exercise tolerance · chronic obstructive pulmonary disease (COPD) with depression

1 finding from 1 review

Pharmacological interventions for the treatment of depression in chronic obstructive pulmonary disease 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 148 participants
Very low

Selective serotonin reuptake inhibitors vs placebo

Change in hospital utilisation ‐ not measured · chronic obstructive pulmonary disease (COPD) with depression

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for the treatment of depression in chronic obstructive pulmonary disease 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Selective serotonin reuptake inhibitors vs placebo

Depressive symptoms · chronic obstructive pulmonary disease (COPD) with depression

1 finding from 1 review

Pharmacological interventions for the treatment of depression in chronic obstructive pulmonary disease 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 148 participants
Very low

Selective serotonin reuptake inhibitors vs placebo

Adverse events (nausea, dizziness) · chronic obstructive pulmonary disease (COPD) with depression

1 finding from 1 review

Pharmacological interventions for the treatment of depression in chronic obstructive pulmonary disease 2018 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 171 participants
Very low

Once‐daily ICS/LABA combined inhalers vs once‐daily LAMA

Mortality (all‐cause) · patients with chronic obstructive pulmonary disease

It is very uncertain whether once‐daily ICS/LABA combined inhalers changes mortality (all‐cause) compared with once‐daily LAMA (very low certainty).

1 finding from 1 review

Once‐daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers versus inhaled long‐acting muscarinic… 2018 · Cochrane Headline outcomes only
OR 0.2 [0.02, 1.73]
2 studies · 880 participants
Very low

Once‐daily ICS/LABA combined inhalers vs once‐daily LAMA

Any COPD exacerbation that requires short‐burst oral corticosteroids or antibiotics, or both · patients with chronic obstructive pulmonary disease

It is very uncertain whether once‐daily ICS/LABA combined inhalers changes any COPD exacerbation that requires short‐burst oral corticosteroids… compared with once‐daily LAMA (very low certainty).

1 finding from 1 review

Once‐daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers versus inhaled long‐acting muscarinic… 2018 · Cochrane Headline outcomes only
OR 0.72 [0.35, 1.5]
2 studies · 880 participants
Very low

Once‐daily ICS/LABA combined inhalers vs once‐daily LAMA

Pneumonia · patients with chronic obstructive pulmonary disease

It is very uncertain whether once‐daily ICS/LABA combined inhalers changes pneumonia compared with once‐daily LAMA (very low certainty).

1 finding from 1 review

Once‐daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers versus inhaled long‐acting muscarinic… 2018 · Cochrane Headline outcomes only
OR 6.12 [0.73, 51.24]
2 studies · 880 participants
Very low

Once‐daily ICS/LABA combined inhalers vs once‐daily LAMA

Quality of life · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Once‐daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers versus inhaled long‐acting muscarinic… 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 779 participants
Very low

Once‐daily ICS/LABA combined inhalers vs once‐daily LAMA

Hospital admissions · patients with chronic obstructive pulmonary disease

It is very uncertain whether once‐daily ICS/LABA combined inhalers changes hospital admissions (all‐cause) compared with once‐daily LAMA (very low certainty).

1 finding from 1 review

Once‐daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers versus inhaled long‐acting muscarinic… 2018 · Cochrane Headline outcomes only
OR 0.96 [0.49, 1.89]
2 studies · 880 participants
Very low

Once‐daily ICS/LABA combined inhalers vs once‐daily LAMA

Exacerbations leading to intubation · patients with chronic obstructive pulmonary disease

The review found no eligible studies for this question.

1 finding from 1 review

Once‐daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers versus inhaled long‐acting muscarinic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Once‐daily ICS/LABA combined inhalers vs once‐daily LAMA

Physical activity measure (e.g. 6MWT) · patients with chronic obstructive pulmonary disease

The review found no eligible studies for this question.

1 finding from 1 review

Once‐daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers versus inhaled long‐acting muscarinic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found